Diana Cirstea

Boston Medical Center — United States

Medicine · Health Sciences

29h-index4.3kcitations188works2.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Myeloma Research and Treatments(116), Protein Degradation and Inhibitors(30), Peptidase Inhibition and Analysis(28), Quinazolinone synthesis and applications(20), Cancer Mechanisms and Therapy(20)

Publications188 total

Prognostic value of serological and PET/CT response kinetics in patients with multiple myeloma treated with BCMA CAR-T
Leukemia·2025Open Access
Choosing the optimal maintenance strategy in multiple myeloma
Hematology·2025Open Access
Validation and refinement of the new high-risk multiple myeloma (HRMM) criteria in relapsed or refractory patients treated with BCMA CAR-T.
Blood·2025Open Access
Single-cell transcriptomics reveal mechanisms of efficacy and toxicity in anti-BCMA CAR-T cell therapies for multiple myeloma
Blood·2025
Deciphering the role of EP300 in maintaining the enhancer landscape and lineage-specific epigenetic vulnerability in multiple myeloma
Blood·2025
First-in-human phase 1 trial of trimeric APRIL (TriPRIL) CAR T cells in relapsed or refractory multiple myeloma: Clinical outcomes and biological correlates of disease response and resistance
Blood·2025Open Access
The efficacy of cilta-cel after a prior BCMA-directed CAR T-cell therapy in relapsed/refractory multiple myeloma
Blood·2025
Immune aging and macrophage inhibitory factor (MIF) – mediated stromal rewiring drives pre-malignant evolution in smoldering multiple myeloma
Blood·2025Open Access
Risk score and survival outcomes for multiple myeloma patients with disease refractory to BCMA CAR-T.
Blood·2025
Deepening responses and MRD-conversion in a phase II fixed-duration consolidation trial of elranatamab post-idecabtagene vicleucel CAR-T cell therapy (EPIC) in relapsed or refractory multiple myeloma
Blood·2025Open Access
Targeted deep sequencing of myeloma in a multi-institutional clinical workflow
Blood·2025Open Access
365 Single-cell transcriptional profiles of cilta-cel and ide-cel associate with response in multiple myeloma
Regular and Young Investigator Award Abstracts·2025Open Access
Impact of body mass index on anti-BCMA chimeric antigen receptor T-cell therapy outcomes in multiple myeloma
Blood Immunology & Cellular Therapy·2025· 1 citedOpen Access
Transdifferentiation From Multiple Myeloma to Myeloid Sarcoma in the Setting of CAR T-Cell Therapy
Clinical Lymphoma Myeloma & Leukemia·2025
Contribution of ARID1A Mutations in the Development of Extramedullary Plasmacytoma
Clinical Lymphoma Myeloma & Leukemia·2025
Non-linear Impact of BMI on Anti-BCMA CAR-T Outcomes: Overweight Paradox in Myeloma
Clinical Lymphoma Myeloma & Leukemia·2025
Initial Results of a Phase 2 Study to Evaluate Elranatamab (elran) Post-Idecabtagene Vicleucel (ide-cel) Consolidation (EPIC) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Clinical Lymphoma Myeloma & Leukemia·2025
First-in-Human Phase 1 Trial of Trimeric APRIL (TriPRIL) CAR-T Cells in Relapsed or Refractory Multiple Myeloma
Clinical Lymphoma Myeloma & Leukemia·2025
Comparison of NGS-Based PlasmaSeq and FISH for Routine Genomic Testing in Multiple Myeloma
Clinical Lymphoma Myeloma & Leukemia·2025
Bispecific Outpatient Step-Up Dosing with Prophylactic Dexamethasone: The BOSS Program Experience in Myeloma
Clinical Lymphoma Myeloma & Leukemia·2025
page 1 of 10Next →

Frequent Co-authors

Noopur Raje(37), Teru Hideshima(29), Nikhil C. Munshi(26), Kenneth C. Anderson(25), Sonia Vallet(17), Güllü Görgün(16), Paul G. Richardson(15), Samantha Pozzi(15), Loredana Santo(13), Andrew J. Yee(12), Hiroshi Ikeda(10), Loredana Santo(10), Homare Eda(9), Naoya Mimura(9), Yiguo Hu(9), Hiroto Ohguchi(9), Yutaka Okawa(9), Giulia Perrone(8), Kishan Patel(8), Mariateresa Fulciniti(7)